NanchangJune 25, 2026 /PRNewswire/ — On June 25, China’s authoritative pharmaceutical media outlet E-Pharmaceutical Manager, in collaboration with Clarivate, released the “2026 China Top 100 Pharmaceutical Innovation Enterprises” list. Jimin Kexin Group, driven by its continuously rising innovation capabilities and densely implemented results, has advanced from the third tier to the second tier compared to the previous year, securing a position in the core camp of China’s pharmaceutical innovation.
Jimin Kexin once again selected among China’s top 100 pharmaceutical innovation enterprises, advancing year by year to the second tier.
The “China Top 100 Pharmaceutical Innovation Enterprises” list, now in its eighth consecutive year of release, is based on a “three-dimensional, four-indicator” evaluation system. It uses objective data such as the number of core patent authorizations for innovative drugs, the number of clinical trials, and the number of innovative drug approvals and launches as assessment criteria. It is one of the most credible annual evaluations in China’s pharmaceutical innovation field. Changes among the top-tier companies on this year’s list are relatively minor, further highlighting the sustained innovation investment and high growth in output of leading enterprises. Jimin Kexin’s leap from the third tier to the second tier is not merely a rise in ranking but also a testament to the maturity of the group’s innovation system and the efficiency of its results transformation, recognized by industry authorities.
Since initiating its transformation and upgrade strategy in 2018, Jimin Kexin has driven sustainable development through innovation. It established a global R&D center in Shanghai’s Zhangjiang Hi-Tech Park, focusing on areas with significant clinical needs such as oncology, cardiovascular and cerebrovascular diseases, and pain management, vigorously advancing innovative drug R&D. The group has successfully built five “Ai+” technology platforms, creating a complete value chain spanning “R&D – clinical trials – internal commercialization.”
Jimin Kexin retains its position on the “China Top 100 Pharmaceutical Innovation Enterprises” list
Jimin Kexin’s innovation strength has not only gained authoritative recognition domestically but has also been widely validated in the international market. In recent years, the company has successfully completed four overseas licensing transactions for innovative drugs, fully demonstrating its competitiveness in global innovative drug R&D. Crucially, Jimin Kexin not only possesses leading R&D capabilities but also has a complete industrialization closed loop. Leveraging its production bases certified by both the NMPA and FDA, along with a mature marketing system, the group provides systematic guarantees for innovative achievements to move from the laboratory to the global market, achieving efficient transformation from “innovative R&D” to “value realization.”
Looking ahead, Jimin Kexin will continue to deepen its differentiated innovation strategy, accelerate pipeline development, contribute to the high-quality development of China’s pharmaceutical industry, and provide more high-quality clinical solutions for patients worldwide.